nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—AOX1—prostate cancer	0.179	0.487	CbGaD
Raloxifene—ESR2—prostate cancer	0.0726	0.197	CbGaD
Raloxifene—ESR2—Estramustine—prostate cancer	0.065	0.15	CbGbCtD
Raloxifene—CYP19A1—prostate cancer	0.0486	0.132	CbGaD
Raloxifene—ESR1—prostate cancer	0.0447	0.122	CbGaD
Raloxifene—ESR2—Estrone—prostate cancer	0.0419	0.0969	CbGbCtD
Raloxifene—ESR2—Ethinyl Estradiol—prostate cancer	0.0373	0.0864	CbGbCtD
Raloxifene—AOX1—Ethinyl Estradiol—prostate cancer	0.0333	0.0771	CbGbCtD
Raloxifene—ESR1—Estramustine—prostate cancer	0.0333	0.0771	CbGbCtD
Raloxifene—ESR2—Conjugated Estrogens—prostate cancer	0.0274	0.0634	CbGbCtD
Raloxifene—ESR2—Estradiol—prostate cancer	0.024	0.0557	CbGbCtD
Raloxifene—CYP3A4—prostate cancer	0.0228	0.0621	CbGaD
Raloxifene—AOX1—Estradiol—prostate cancer	0.0214	0.0497	CbGbCtD
Raloxifene—ESR1—Estrone—prostate cancer	0.0214	0.0497	CbGbCtD
Raloxifene—ESR1—Ethinyl Estradiol—prostate cancer	0.0191	0.0443	CbGbCtD
Raloxifene—ESR1—Conjugated Estrogens—prostate cancer	0.014	0.0325	CbGbCtD
Raloxifene—ESR1—Estradiol—prostate cancer	0.0123	0.0285	CbGbCtD
Raloxifene—CYP2C8—Nilutamide—prostate cancer	0.00907	0.021	CbGbCtD
Raloxifene—CYP2C8—Abiraterone—prostate cancer	0.00751	0.0174	CbGbCtD
Raloxifene—CYP2B6—Estrone—prostate cancer	0.00717	0.0166	CbGbCtD
Raloxifene—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.007	0.0162	CbGbCtD
Raloxifene—CYP2B6—Ethinyl Estradiol—prostate cancer	0.00639	0.0148	CbGbCtD
Raloxifene—CYP2C8—Cabazitaxel—prostate cancer	0.00556	0.0129	CbGbCtD
Raloxifene—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00484	0.0112	CbGbCtD
Raloxifene—CYP3A4—Bicalutamide—prostate cancer	0.00368	0.00851	CbGbCtD
Raloxifene—CYP3A4—Estramustine—prostate cancer	0.00342	0.00791	CbGbCtD
Raloxifene—CYP2C8—Estradiol—prostate cancer	0.00312	0.00722	CbGbCtD
Raloxifene—CYP3A4—Flutamide—prostate cancer	0.00305	0.00705	CbGbCtD
Raloxifene—CYP3A4—Abiraterone—prostate cancer	0.00305	0.00705	CbGbCtD
Raloxifene—CYP19A1—semen—prostate cancer	0.00256	0.162	CbGeAlD
Raloxifene—CYP3A4—Cabazitaxel—prostate cancer	0.00225	0.00522	CbGbCtD
Raloxifene—CYP3A4—Estrone—prostate cancer	0.0022	0.0051	CbGbCtD
Raloxifene—CYP2C8—Etoposide—prostate cancer	0.00204	0.00472	CbGbCtD
Raloxifene—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00196	0.00455	CbGbCtD
Raloxifene—CYP2B6—Doxorubicin—prostate cancer	0.00183	0.00425	CbGbCtD
Raloxifene—CYP3A4—Conjugated Estrogens—prostate cancer	0.00144	0.00334	CbGbCtD
Raloxifene—CYP3A4—Mitoxantrone—prostate cancer	0.00131	0.00303	CbGbCtD
Raloxifene—CYP3A4—Estradiol—prostate cancer	0.00127	0.00293	CbGbCtD
Raloxifene—CYP3A4—Prednisone—prostate cancer	0.00109	0.00252	CbGbCtD
Raloxifene—CYP3A4—urine—prostate cancer	0.000869	0.0549	CbGeAlD
Raloxifene—CYP3A4—Etoposide—prostate cancer	0.000826	0.00191	CbGbCtD
Raloxifene—ESR2—prostate gland—prostate cancer	0.000816	0.0515	CbGeAlD
Raloxifene—AOX1—prostate gland—prostate cancer	0.000785	0.0496	CbGeAlD
Raloxifene—CYP3A4—Docetaxel—prostate cancer	0.000756	0.00175	CbGbCtD
Raloxifene—SIGMAR1—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.00071	1	CbGdCrCtD
Raloxifene—Flavoxate—PDE4D—prostate cancer	0.000684	1	CrCbGaD
Raloxifene—AOX1—seminal vesicle—prostate cancer	0.000664	0.042	CbGeAlD
Raloxifene—CYP19A1—prostate gland—prostate cancer	0.000643	0.0406	CbGeAlD
Raloxifene—SIGMAR1—prostate gland—prostate cancer	0.000632	0.0399	CbGeAlD
Raloxifene—ESR2—epithelium—prostate cancer	0.0006	0.0379	CbGeAlD
Raloxifene—CYP3A4—Doxorubicin—prostate cancer	0.000563	0.0013	CbGbCtD
Raloxifene—ESR1—prostate gland—prostate cancer	0.000559	0.0353	CbGeAlD
Raloxifene—ESR2—renal system—prostate cancer	0.000556	0.0351	CbGeAlD
Raloxifene—AOX1—renal system—prostate cancer	0.000535	0.0338	CbGeAlD
Raloxifene—SIGMAR1—seminal vesicle—prostate cancer	0.000535	0.0338	CbGeAlD
Raloxifene—AOX1—urethra—prostate cancer	0.000526	0.0332	CbGeAlD
Raloxifene—SIGMAR1—urethra—prostate cancer	0.000423	0.0267	CbGeAlD
Raloxifene—ESR1—epithelium—prostate cancer	0.000411	0.0259	CbGeAlD
Raloxifene—ESR1—renal system—prostate cancer	0.000381	0.0241	CbGeAlD
Raloxifene—ESR2—testis—prostate cancer	0.000359	0.0227	CbGeAlD
Raloxifene—AOX1—testis—prostate cancer	0.000346	0.0219	CbGeAlD
Raloxifene—SIGMAR1—bone marrow—prostate cancer	0.000326	0.0206	CbGeAlD
Raloxifene—CYP2C8—renal system—prostate cancer	0.000314	0.0198	CbGeAlD
Raloxifene—CYP19A1—testis—prostate cancer	0.000283	0.0179	CbGeAlD
Raloxifene—CYP2B6—renal system—prostate cancer	0.000281	0.0178	CbGeAlD
Raloxifene—SIGMAR1—testis—prostate cancer	0.000278	0.0176	CbGeAlD
Raloxifene—ESR2—lymph node—prostate cancer	0.000261	0.0165	CbGeAlD
Raloxifene—AOX1—lymph node—prostate cancer	0.000251	0.0158	CbGeAlD
Raloxifene—ESR1—testis—prostate cancer	0.000246	0.0156	CbGeAlD
Raloxifene—CYP3A4—renal system—prostate cancer	0.000213	0.0134	CbGeAlD
Raloxifene—CYP19A1—lymph node—prostate cancer	0.000205	0.013	CbGeAlD
Raloxifene—CYP2C8—testis—prostate cancer	0.000203	0.0128	CbGeAlD
Raloxifene—SIGMAR1—lymph node—prostate cancer	0.000202	0.0128	CbGeAlD
Raloxifene—HTR2B—lymph node—prostate cancer	0.000201	0.0127	CbGeAlD
Raloxifene—CYP2B6—testis—prostate cancer	0.000182	0.0115	CbGeAlD
Raloxifene—ESR1—lymph node—prostate cancer	0.000178	0.0113	CbGeAlD
Raloxifene—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	4.17e-05	0.000365	CcSEcCtD
Raloxifene—Cardiac disorder—Docetaxel—prostate cancer	4.14e-05	0.000362	CcSEcCtD
Raloxifene—Flushing—Docetaxel—prostate cancer	4.14e-05	0.000362	CcSEcCtD
Raloxifene—Loss of consciousness—Etoposide—prostate cancer	4.1e-05	0.000359	CcSEcCtD
Raloxifene—Cerebrovascular accident—Doxorubicin—prostate cancer	4.1e-05	0.000359	CcSEcCtD
Raloxifene—Dizziness—Goserelin—prostate cancer	4.1e-05	0.000359	CcSEcCtD
Raloxifene—Cough—Etoposide—prostate cancer	4.08e-05	0.000356	CcSEcCtD
Raloxifene—Dizziness—Conjugated Estrogens—prostate cancer	4.06e-05	0.000355	CcSEcCtD
Raloxifene—Angiopathy—Docetaxel—prostate cancer	4.05e-05	0.000354	CcSEcCtD
Raloxifene—Dyspepsia—Mitoxantrone—prostate cancer	4.03e-05	0.000353	CcSEcCtD
Raloxifene—Gastrointestinal pain—Estradiol—prostate cancer	4.02e-05	0.000351	CcSEcCtD
Raloxifene—Flushing—Capecitabine—prostate cancer	4.01e-05	0.00035	CcSEcCtD
Raloxifene—Cardiac disorder—Capecitabine—prostate cancer	4.01e-05	0.00035	CcSEcCtD
Raloxifene—Chest pain—Etoposide—prostate cancer	3.98e-05	0.000347	CcSEcCtD
Raloxifene—Migraine—Doxorubicin—prostate cancer	3.96e-05	0.000346	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	3.95e-05	0.000345	CcSEcCtD
Raloxifene—Vomiting—Goserelin—prostate cancer	3.94e-05	0.000345	CcSEcCtD
Raloxifene—Breast disorder—Epirubicin—prostate cancer	3.93e-05	0.000343	CcSEcCtD
Raloxifene—Pain—Mitoxantrone—prostate cancer	3.92e-05	0.000342	CcSEcCtD
Raloxifene—Angiopathy—Capecitabine—prostate cancer	3.92e-05	0.000342	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Epirubicin—prostate cancer	3.91e-05	0.000342	CcSEcCtD
Raloxifene—Rash—Goserelin—prostate cancer	3.91e-05	0.000342	CcSEcCtD
Raloxifene—Dermatitis—Goserelin—prostate cancer	3.91e-05	0.000342	CcSEcCtD
Raloxifene—Vomiting—Conjugated Estrogens—prostate cancer	3.91e-05	0.000341	CcSEcCtD
Raloxifene—Abdominal pain—Estradiol—prostate cancer	3.89e-05	0.00034	CcSEcCtD
Raloxifene—Body temperature increased—Estradiol—prostate cancer	3.89e-05	0.00034	CcSEcCtD
Raloxifene—Headache—Goserelin—prostate cancer	3.89e-05	0.00034	CcSEcCtD
Raloxifene—Rash—Conjugated Estrogens—prostate cancer	3.87e-05	0.000339	CcSEcCtD
Raloxifene—Dermatitis—Conjugated Estrogens—prostate cancer	3.87e-05	0.000338	CcSEcCtD
Raloxifene—Headache—Conjugated Estrogens—prostate cancer	3.85e-05	0.000336	CcSEcCtD
Raloxifene—Infection—Etoposide—prostate cancer	3.79e-05	0.000331	CcSEcCtD
Raloxifene—Connective tissue disorder—Prednisone—prostate cancer	3.78e-05	0.00033	CcSEcCtD
Raloxifene—Influenza—Epirubicin—prostate cancer	3.76e-05	0.000328	CcSEcCtD
Raloxifene—Gastrointestinal pain—Mitoxantrone—prostate cancer	3.75e-05	0.000327	CcSEcCtD
Raloxifene—Thrombocytopenia—Etoposide—prostate cancer	3.73e-05	0.000326	CcSEcCtD
Raloxifene—Muscle spasms—Docetaxel—prostate cancer	3.73e-05	0.000326	CcSEcCtD
Raloxifene—Flatulence—Capecitabine—prostate cancer	3.7e-05	0.000324	CcSEcCtD
Raloxifene—Skin disorder—Etoposide—prostate cancer	3.7e-05	0.000324	CcSEcCtD
Raloxifene—Nausea—Goserelin—prostate cancer	3.68e-05	0.000322	CcSEcCtD
Raloxifene—Hyperhidrosis—Etoposide—prostate cancer	3.68e-05	0.000322	CcSEcCtD
Raloxifene—Nausea—Conjugated Estrogens—prostate cancer	3.65e-05	0.000319	CcSEcCtD
Raloxifene—Breast disorder—Doxorubicin—prostate cancer	3.63e-05	0.000318	CcSEcCtD
Raloxifene—Body temperature increased—Mitoxantrone—prostate cancer	3.62e-05	0.000317	CcSEcCtD
Raloxifene—Abdominal pain—Mitoxantrone—prostate cancer	3.62e-05	0.000317	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	3.62e-05	0.000317	CcSEcCtD
Raloxifene—Bronchitis—Epirubicin—prostate cancer	3.61e-05	0.000316	CcSEcCtD
Raloxifene—Muscle spasms—Capecitabine—prostate cancer	3.61e-05	0.000316	CcSEcCtD
Raloxifene—Flushing—Prednisone—prostate cancer	3.57e-05	0.000312	CcSEcCtD
Raloxifene—Angiopathy—Prednisone—prostate cancer	3.49e-05	0.000305	CcSEcCtD
Raloxifene—Syncope—Docetaxel—prostate cancer	3.48e-05	0.000304	CcSEcCtD
Raloxifene—Influenza—Doxorubicin—prostate cancer	3.48e-05	0.000304	CcSEcCtD
Raloxifene—Weight increased—Epirubicin—prostate cancer	3.42e-05	0.000299	CcSEcCtD
Raloxifene—Loss of consciousness—Docetaxel—prostate cancer	3.41e-05	0.000298	CcSEcCtD
Raloxifene—Cough—Docetaxel—prostate cancer	3.39e-05	0.000296	CcSEcCtD
Raloxifene—Vertigo—Capecitabine—prostate cancer	3.38e-05	0.000295	CcSEcCtD
Raloxifene—Syncope—Capecitabine—prostate cancer	3.37e-05	0.000294	CcSEcCtD
Raloxifene—Pneumonia—Epirubicin—prostate cancer	3.37e-05	0.000294	CcSEcCtD
Raloxifene—Diarrhoea—Estradiol—prostate cancer	3.36e-05	0.000294	CcSEcCtD
Raloxifene—Bronchitis—Doxorubicin—prostate cancer	3.34e-05	0.000292	CcSEcCtD
Raloxifene—Chest pain—Docetaxel—prostate cancer	3.3e-05	0.000289	CcSEcCtD
Raloxifene—Myalgia—Docetaxel—prostate cancer	3.3e-05	0.000289	CcSEcCtD
Raloxifene—Arthralgia—Docetaxel—prostate cancer	3.3e-05	0.000289	CcSEcCtD
Raloxifene—Loss of consciousness—Capecitabine—prostate cancer	3.3e-05	0.000289	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Etoposide—prostate cancer	3.29e-05	0.000288	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	3.28e-05	0.000287	CcSEcCtD
Raloxifene—Cough—Capecitabine—prostate cancer	3.28e-05	0.000287	CcSEcCtD
Raloxifene—Pain—Etoposide—prostate cancer	3.26e-05	0.000285	CcSEcCtD
Raloxifene—Conjunctivitis—Epirubicin—prostate cancer	3.26e-05	0.000285	CcSEcCtD
Raloxifene—Urinary tract infection—Epirubicin—prostate cancer	3.26e-05	0.000285	CcSEcCtD
Raloxifene—Dizziness—Estradiol—prostate cancer	3.25e-05	0.000284	CcSEcCtD
Raloxifene—Sweating—Epirubicin—prostate cancer	3.21e-05	0.000281	CcSEcCtD
Raloxifene—Arthralgia—Capecitabine—prostate cancer	3.2e-05	0.00028	CcSEcCtD
Raloxifene—Myalgia—Capecitabine—prostate cancer	3.2e-05	0.00028	CcSEcCtD
Raloxifene—Chest pain—Capecitabine—prostate cancer	3.2e-05	0.00028	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	3.18e-05	0.000278	CcSEcCtD
Raloxifene—Weight increased—Doxorubicin—prostate cancer	3.16e-05	0.000276	CcSEcCtD
Raloxifene—Infection—Docetaxel—prostate cancer	3.15e-05	0.000275	CcSEcCtD
Raloxifene—Sinusitis—Epirubicin—prostate cancer	3.14e-05	0.000275	CcSEcCtD
Raloxifene—Diarrhoea—Mitoxantrone—prostate cancer	3.14e-05	0.000274	CcSEcCtD
Raloxifene—Vomiting—Estradiol—prostate cancer	3.13e-05	0.000273	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—prostate cancer	3.12e-05	0.000272	CcSEcCtD
Raloxifene—Gastrointestinal pain—Etoposide—prostate cancer	3.12e-05	0.000272	CcSEcCtD
Raloxifene—Shock—Docetaxel—prostate cancer	3.12e-05	0.000272	CcSEcCtD
Raloxifene—Nervous system disorder—Docetaxel—prostate cancer	3.11e-05	0.000271	CcSEcCtD
Raloxifene—Thrombocytopenia—Docetaxel—prostate cancer	3.1e-05	0.000271	CcSEcCtD
Raloxifene—Rash—Estradiol—prostate cancer	3.1e-05	0.000271	CcSEcCtD
Raloxifene—Dermatitis—Estradiol—prostate cancer	3.1e-05	0.000271	CcSEcCtD
Raloxifene—Headache—Estradiol—prostate cancer	3.08e-05	0.000269	CcSEcCtD
Raloxifene—Skin disorder—Docetaxel—prostate cancer	3.08e-05	0.000269	CcSEcCtD
Raloxifene—Infection—Capecitabine—prostate cancer	3.05e-05	0.000266	CcSEcCtD
Raloxifene—Shock—Capecitabine—prostate cancer	3.02e-05	0.000264	CcSEcCtD
Raloxifene—Rhinitis—Epirubicin—prostate cancer	3.01e-05	0.000263	CcSEcCtD
Raloxifene—Abdominal pain—Etoposide—prostate cancer	3.01e-05	0.000263	CcSEcCtD
Raloxifene—Body temperature increased—Etoposide—prostate cancer	3.01e-05	0.000263	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—prostate cancer	3.01e-05	0.000263	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—prostate cancer	3.01e-05	0.000263	CcSEcCtD
Raloxifene—Nervous system disorder—Capecitabine—prostate cancer	3.01e-05	0.000263	CcSEcCtD
Raloxifene—Vertigo—Prednisone—prostate cancer	3.01e-05	0.000263	CcSEcCtD
Raloxifene—Thrombocytopenia—Capecitabine—prostate cancer	3e-05	0.000262	CcSEcCtD
Raloxifene—Syncope—Prednisone—prostate cancer	3e-05	0.000262	CcSEcCtD
Raloxifene—Hypoaesthesia—Epirubicin—prostate cancer	2.99e-05	0.000261	CcSEcCtD
Raloxifene—Pharyngitis—Epirubicin—prostate cancer	2.98e-05	0.000261	CcSEcCtD
Raloxifene—Skin disorder—Capecitabine—prostate cancer	2.98e-05	0.00026	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—prostate cancer	2.97e-05	0.00026	CcSEcCtD
Raloxifene—Urinary tract disorder—Epirubicin—prostate cancer	2.97e-05	0.00026	CcSEcCtD
Raloxifene—Hyperhidrosis—Capecitabine—prostate cancer	2.96e-05	0.000259	CcSEcCtD
Raloxifene—Oedema peripheral—Epirubicin—prostate cancer	2.96e-05	0.000259	CcSEcCtD
Raloxifene—Connective tissue disorder—Epirubicin—prostate cancer	2.96e-05	0.000258	CcSEcCtD
Raloxifene—Urethral disorder—Epirubicin—prostate cancer	2.95e-05	0.000258	CcSEcCtD
Raloxifene—Loss of consciousness—Prednisone—prostate cancer	2.94e-05	0.000257	CcSEcCtD
Raloxifene—Nausea—Estradiol—prostate cancer	2.92e-05	0.000255	CcSEcCtD
Raloxifene—Vomiting—Mitoxantrone—prostate cancer	2.91e-05	0.000255	CcSEcCtD
Raloxifene—Sinusitis—Doxorubicin—prostate cancer	2.91e-05	0.000254	CcSEcCtD
Raloxifene—Rash—Mitoxantrone—prostate cancer	2.89e-05	0.000252	CcSEcCtD
Raloxifene—Dermatitis—Mitoxantrone—prostate cancer	2.89e-05	0.000252	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.89e-05	0.000252	CcSEcCtD
Raloxifene—Headache—Mitoxantrone—prostate cancer	2.87e-05	0.000251	CcSEcCtD
Raloxifene—Insomnia—Docetaxel—prostate cancer	2.86e-05	0.00025	CcSEcCtD
Raloxifene—Myalgia—Prednisone—prostate cancer	2.85e-05	0.000249	CcSEcCtD
Raloxifene—Arthralgia—Prednisone—prostate cancer	2.85e-05	0.000249	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.83e-05	0.000247	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.79e-05	0.000244	CcSEcCtD
Raloxifene—Cardiac disorder—Epirubicin—prostate cancer	2.79e-05	0.000244	CcSEcCtD
Raloxifene—Flushing—Epirubicin—prostate cancer	2.79e-05	0.000244	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—prostate cancer	2.79e-05	0.000244	CcSEcCtD
Raloxifene—Dyspepsia—Docetaxel—prostate cancer	2.79e-05	0.000244	CcSEcCtD
Raloxifene—Insomnia—Capecitabine—prostate cancer	2.77e-05	0.000242	CcSEcCtD
Raloxifene—Hypoaesthesia—Doxorubicin—prostate cancer	2.77e-05	0.000242	CcSEcCtD
Raloxifene—Pharyngitis—Doxorubicin—prostate cancer	2.76e-05	0.000241	CcSEcCtD
Raloxifene—Urinary tract disorder—Doxorubicin—prostate cancer	2.75e-05	0.00024	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—prostate cancer	2.74e-05	0.00024	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Docetaxel—prostate cancer	2.73e-05	0.000239	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—prostate cancer	2.73e-05	0.000239	CcSEcCtD
Raloxifene—Angiopathy—Epirubicin—prostate cancer	2.73e-05	0.000238	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—prostate cancer	2.73e-05	0.000238	CcSEcCtD
Raloxifene—Nausea—Mitoxantrone—prostate cancer	2.72e-05	0.000238	CcSEcCtD
Raloxifene—Infection—Prednisone—prostate cancer	2.71e-05	0.000237	CcSEcCtD
Raloxifene—Pain—Docetaxel—prostate cancer	2.71e-05	0.000237	CcSEcCtD
Raloxifene—Dyspepsia—Capecitabine—prostate cancer	2.7e-05	0.000236	CcSEcCtD
Raloxifene—Shock—Prednisone—prostate cancer	2.69e-05	0.000235	CcSEcCtD
Raloxifene—Nervous system disorder—Prednisone—prostate cancer	2.68e-05	0.000234	CcSEcCtD
Raloxifene—Skin disorder—Prednisone—prostate cancer	2.65e-05	0.000232	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Capecitabine—prostate cancer	2.65e-05	0.000231	CcSEcCtD
Raloxifene—Hyperhidrosis—Prednisone—prostate cancer	2.64e-05	0.000231	CcSEcCtD
Raloxifene—Pain—Capecitabine—prostate cancer	2.62e-05	0.000229	CcSEcCtD
Raloxifene—Diarrhoea—Etoposide—prostate cancer	2.61e-05	0.000228	CcSEcCtD
Raloxifene—Gastrointestinal pain—Docetaxel—prostate cancer	2.59e-05	0.000226	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—prostate cancer	2.58e-05	0.000226	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—prostate cancer	2.58e-05	0.000226	CcSEcCtD
Raloxifene—Flatulence—Epirubicin—prostate cancer	2.58e-05	0.000225	CcSEcCtD
Raloxifene—Angiopathy—Doxorubicin—prostate cancer	2.52e-05	0.000221	CcSEcCtD
Raloxifene—Dizziness—Etoposide—prostate cancer	2.52e-05	0.00022	CcSEcCtD
Raloxifene—Muscle spasms—Epirubicin—prostate cancer	2.52e-05	0.00022	CcSEcCtD
Raloxifene—Gastrointestinal pain—Capecitabine—prostate cancer	2.51e-05	0.000219	CcSEcCtD
Raloxifene—Abdominal pain—Docetaxel—prostate cancer	2.5e-05	0.000219	CcSEcCtD
Raloxifene—Body temperature increased—Docetaxel—prostate cancer	2.5e-05	0.000219	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Prednisone—prostate cancer	2.49e-05	0.000218	CcSEcCtD
Raloxifene—Insomnia—Prednisone—prostate cancer	2.47e-05	0.000216	CcSEcCtD
Raloxifene—Abdominal pain—Capecitabine—prostate cancer	2.42e-05	0.000212	CcSEcCtD
Raloxifene—Body temperature increased—Capecitabine—prostate cancer	2.42e-05	0.000212	CcSEcCtD
Raloxifene—Vomiting—Etoposide—prostate cancer	2.42e-05	0.000212	CcSEcCtD
Raloxifene—Dyspepsia—Prednisone—prostate cancer	2.4e-05	0.00021	CcSEcCtD
Raloxifene—Rash—Etoposide—prostate cancer	2.4e-05	0.00021	CcSEcCtD
Raloxifene—Dermatitis—Etoposide—prostate cancer	2.4e-05	0.00021	CcSEcCtD
Raloxifene—Headache—Etoposide—prostate cancer	2.39e-05	0.000209	CcSEcCtD
Raloxifene—Flatulence—Doxorubicin—prostate cancer	2.39e-05	0.000209	CcSEcCtD
Raloxifene—Vertigo—Epirubicin—prostate cancer	2.35e-05	0.000206	CcSEcCtD
Raloxifene—Syncope—Epirubicin—prostate cancer	2.35e-05	0.000205	CcSEcCtD
Raloxifene—Muscle spasms—Doxorubicin—prostate cancer	2.33e-05	0.000204	CcSEcCtD
Raloxifene—Loss of consciousness—Epirubicin—prostate cancer	2.3e-05	0.000201	CcSEcCtD
Raloxifene—Cough—Epirubicin—prostate cancer	2.28e-05	0.0002	CcSEcCtD
Raloxifene—Nausea—Etoposide—prostate cancer	2.26e-05	0.000198	CcSEcCtD
Raloxifene—Gastrointestinal pain—Prednisone—prostate cancer	2.23e-05	0.000195	CcSEcCtD
Raloxifene—Chest pain—Epirubicin—prostate cancer	2.23e-05	0.000195	CcSEcCtD
Raloxifene—Arthralgia—Epirubicin—prostate cancer	2.23e-05	0.000195	CcSEcCtD
Raloxifene—Myalgia—Epirubicin—prostate cancer	2.23e-05	0.000195	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.21e-05	0.000193	CcSEcCtD
Raloxifene—Vertigo—Doxorubicin—prostate cancer	2.18e-05	0.00019	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—prostate cancer	2.17e-05	0.00019	CcSEcCtD
Raloxifene—Diarrhoea—Docetaxel—prostate cancer	2.17e-05	0.000189	CcSEcCtD
Raloxifene—Body temperature increased—Prednisone—prostate cancer	2.16e-05	0.000189	CcSEcCtD
Raloxifene—Abdominal pain—Prednisone—prostate cancer	2.16e-05	0.000189	CcSEcCtD
Raloxifene—Loss of consciousness—Doxorubicin—prostate cancer	2.13e-05	0.000186	CcSEcCtD
Raloxifene—Infection—Epirubicin—prostate cancer	2.12e-05	0.000185	CcSEcCtD
Raloxifene—Cough—Doxorubicin—prostate cancer	2.11e-05	0.000185	CcSEcCtD
Raloxifene—Shock—Epirubicin—prostate cancer	2.1e-05	0.000184	CcSEcCtD
Raloxifene—Diarrhoea—Capecitabine—prostate cancer	2.1e-05	0.000183	CcSEcCtD
Raloxifene—Nervous system disorder—Epirubicin—prostate cancer	2.1e-05	0.000183	CcSEcCtD
Raloxifene—Dizziness—Docetaxel—prostate cancer	2.09e-05	0.000183	CcSEcCtD
Raloxifene—Thrombocytopenia—Epirubicin—prostate cancer	2.09e-05	0.000183	CcSEcCtD
Raloxifene—Skin disorder—Epirubicin—prostate cancer	2.08e-05	0.000181	CcSEcCtD
Raloxifene—Hyperhidrosis—Epirubicin—prostate cancer	2.07e-05	0.000181	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—prostate cancer	2.06e-05	0.00018	CcSEcCtD
Raloxifene—Myalgia—Doxorubicin—prostate cancer	2.06e-05	0.00018	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—prostate cancer	2.06e-05	0.00018	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.05e-05	0.000179	CcSEcCtD
Raloxifene—Dizziness—Capecitabine—prostate cancer	2.03e-05	0.000177	CcSEcCtD
Raloxifene—Vomiting—Docetaxel—prostate cancer	2.01e-05	0.000176	CcSEcCtD
Raloxifene—Rash—Docetaxel—prostate cancer	2e-05	0.000175	CcSEcCtD
Raloxifene—Dermatitis—Docetaxel—prostate cancer	2e-05	0.000174	CcSEcCtD
Raloxifene—Headache—Docetaxel—prostate cancer	1.98e-05	0.000173	CcSEcCtD
Raloxifene—Infection—Doxorubicin—prostate cancer	1.96e-05	0.000172	CcSEcCtD
Raloxifene—Vomiting—Capecitabine—prostate cancer	1.95e-05	0.00017	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.95e-05	0.00017	CcSEcCtD
Raloxifene—Shock—Doxorubicin—prostate cancer	1.94e-05	0.00017	CcSEcCtD
Raloxifene—Nervous system disorder—Doxorubicin—prostate cancer	1.94e-05	0.000169	CcSEcCtD
Raloxifene—Thrombocytopenia—Doxorubicin—prostate cancer	1.94e-05	0.000169	CcSEcCtD
Raloxifene—Rash—Capecitabine—prostate cancer	1.93e-05	0.000169	CcSEcCtD
Raloxifene—Insomnia—Epirubicin—prostate cancer	1.93e-05	0.000169	CcSEcCtD
Raloxifene—Dermatitis—Capecitabine—prostate cancer	1.93e-05	0.000169	CcSEcCtD
Raloxifene—Headache—Capecitabine—prostate cancer	1.92e-05	0.000168	CcSEcCtD
Raloxifene—Skin disorder—Doxorubicin—prostate cancer	1.92e-05	0.000168	CcSEcCtD
Raloxifene—Hyperhidrosis—Doxorubicin—prostate cancer	1.91e-05	0.000167	CcSEcCtD
Raloxifene—Nausea—Docetaxel—prostate cancer	1.88e-05	0.000164	CcSEcCtD
Raloxifene—Dyspepsia—Epirubicin—prostate cancer	1.88e-05	0.000164	CcSEcCtD
Raloxifene—Diarrhoea—Prednisone—prostate cancer	1.87e-05	0.000163	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Epirubicin—prostate cancer	1.84e-05	0.000161	CcSEcCtD
Raloxifene—Pain—Epirubicin—prostate cancer	1.83e-05	0.00016	CcSEcCtD
Raloxifene—Nausea—Capecitabine—prostate cancer	1.82e-05	0.000159	CcSEcCtD
Raloxifene—Dizziness—Prednisone—prostate cancer	1.81e-05	0.000158	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.8e-05	0.000157	CcSEcCtD
Raloxifene—Insomnia—Doxorubicin—prostate cancer	1.79e-05	0.000156	CcSEcCtD
Raloxifene—Gastrointestinal pain—Epirubicin—prostate cancer	1.75e-05	0.000153	CcSEcCtD
Raloxifene—Dyspepsia—Doxorubicin—prostate cancer	1.74e-05	0.000152	CcSEcCtD
Raloxifene—Vomiting—Prednisone—prostate cancer	1.74e-05	0.000152	CcSEcCtD
Raloxifene—Rash—Prednisone—prostate cancer	1.72e-05	0.000151	CcSEcCtD
Raloxifene—Dermatitis—Prednisone—prostate cancer	1.72e-05	0.00015	CcSEcCtD
Raloxifene—Headache—Prednisone—prostate cancer	1.71e-05	0.00015	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.71e-05	0.000149	CcSEcCtD
Raloxifene—Pain—Doxorubicin—prostate cancer	1.69e-05	0.000148	CcSEcCtD
Raloxifene—Abdominal pain—Epirubicin—prostate cancer	1.69e-05	0.000148	CcSEcCtD
Raloxifene—Body temperature increased—Epirubicin—prostate cancer	1.69e-05	0.000148	CcSEcCtD
Raloxifene—Nausea—Prednisone—prostate cancer	1.62e-05	0.000142	CcSEcCtD
Raloxifene—Gastrointestinal pain—Doxorubicin—prostate cancer	1.62e-05	0.000141	CcSEcCtD
Raloxifene—Abdominal pain—Doxorubicin—prostate cancer	1.56e-05	0.000137	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—prostate cancer	1.56e-05	0.000137	CcSEcCtD
Raloxifene—Diarrhoea—Epirubicin—prostate cancer	1.46e-05	0.000128	CcSEcCtD
Raloxifene—Dizziness—Epirubicin—prostate cancer	1.41e-05	0.000123	CcSEcCtD
Raloxifene—Vomiting—Epirubicin—prostate cancer	1.36e-05	0.000119	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—prostate cancer	1.35e-05	0.000118	CcSEcCtD
Raloxifene—Rash—Epirubicin—prostate cancer	1.35e-05	0.000118	CcSEcCtD
Raloxifene—Dermatitis—Epirubicin—prostate cancer	1.35e-05	0.000118	CcSEcCtD
Raloxifene—Headache—Epirubicin—prostate cancer	1.34e-05	0.000117	CcSEcCtD
Raloxifene—Dizziness—Doxorubicin—prostate cancer	1.31e-05	0.000114	CcSEcCtD
Raloxifene—Nausea—Epirubicin—prostate cancer	1.27e-05	0.000111	CcSEcCtD
Raloxifene—Vomiting—Doxorubicin—prostate cancer	1.26e-05	0.00011	CcSEcCtD
Raloxifene—Rash—Doxorubicin—prostate cancer	1.25e-05	0.000109	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—prostate cancer	1.25e-05	0.000109	CcSEcCtD
Raloxifene—Headache—Doxorubicin—prostate cancer	1.24e-05	0.000108	CcSEcCtD
Raloxifene—Nausea—Doxorubicin—prostate cancer	1.17e-05	0.000103	CcSEcCtD
Raloxifene—HTR6—Signaling Pathways—CREBBP—prostate cancer	1.99e-06	2.88e-05	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CA—prostate cancer	1.97e-06	2.85e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IGF1—prostate cancer	1.96e-06	2.84e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APC—prostate cancer	1.96e-06	2.83e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CG—prostate cancer	1.96e-06	2.83e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—EGFR—prostate cancer	1.95e-06	2.83e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC22A3—prostate cancer	1.94e-06	2.82e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HSD3B1—prostate cancer	1.94e-06	2.82e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TERT—prostate cancer	1.93e-06	2.8e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IRS1—prostate cancer	1.93e-06	2.8e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGF—prostate cancer	1.93e-06	2.8e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GGT1—prostate cancer	1.93e-06	2.8e-05	CbGpPWpGaD
Raloxifene—AOX1—Disease—AKT1—prostate cancer	1.92e-06	2.78e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CD—prostate cancer	1.91e-06	2.77e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TYMS—prostate cancer	1.9e-06	2.76e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NCOA1—prostate cancer	1.9e-06	2.76e-05	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—AKT1—prostate cancer	1.9e-06	2.75e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAP2K1—prostate cancer	1.9e-06	2.75e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CD—prostate cancer	1.88e-06	2.73e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTM1—prostate cancer	1.88e-06	2.73e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—GSK3B—prostate cancer	1.88e-06	2.72e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP19A1—prostate cancer	1.87e-06	2.72e-05	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CA—prostate cancer	1.87e-06	2.7e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SERPINE1—prostate cancer	1.86e-06	2.7e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTA4—prostate cancer	1.86e-06	2.7e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TBXAS1—prostate cancer	1.86e-06	2.7e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—INS—prostate cancer	1.85e-06	2.68e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HIF1A—prostate cancer	1.85e-06	2.68e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—LPL—prostate cancer	1.85e-06	2.68e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—KRAS—prostate cancer	1.84e-06	2.67e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTA2—prostate cancer	1.82e-06	2.63e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CREBBP—prostate cancer	1.81e-06	2.63e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—RXRA—prostate cancer	1.81e-06	2.62e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—NOS3—prostate cancer	1.81e-06	2.62e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—LEP—prostate cancer	1.81e-06	2.62e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FGF2—prostate cancer	1.8e-06	2.61e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SULT1A1—prostate cancer	1.79e-06	2.6e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCG5—prostate cancer	1.79e-06	2.6e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IGF1—prostate cancer	1.79e-06	2.59e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CAV1—prostate cancer	1.79e-06	2.59e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP1A1—prostate cancer	1.78e-06	2.59e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—EGFR—prostate cancer	1.78e-06	2.58e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NOS3—prostate cancer	1.78e-06	2.58e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ERCC2—prostate cancer	1.77e-06	2.56e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KDR—prostate cancer	1.77e-06	2.56e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.76e-06	2.55e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTA1—prostate cancer	1.75e-06	2.54e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—COMT—prostate cancer	1.74e-06	2.52e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTP1—prostate cancer	1.73e-06	2.51e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTO1—prostate cancer	1.73e-06	2.51e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NAT2—prostate cancer	1.73e-06	2.51e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HSD3B2—prostate cancer	1.73e-06	2.51e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAP2K1—prostate cancer	1.73e-06	2.51e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—JAK2—prostate cancer	1.73e-06	2.5e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CD—prostate cancer	1.72e-06	2.49e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ITPR1—prostate cancer	1.71e-06	2.47e-05	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CA—prostate cancer	1.7e-06	2.47e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SERPINE1—prostate cancer	1.7e-06	2.46e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CA—prostate cancer	1.69e-06	2.45e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MDM2—prostate cancer	1.69e-06	2.44e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—KRAS—prostate cancer	1.68e-06	2.44e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—BAD—prostate cancer	1.68e-06	2.44e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.68e-06	2.43e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CB—prostate cancer	1.67e-06	2.42e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ERBB2—prostate cancer	1.66e-06	2.41e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—MTHFR—prostate cancer	1.66e-06	2.41e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PLCB2—prostate cancer	1.66e-06	2.41e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—LRP2—prostate cancer	1.66e-06	2.41e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP2C18—prostate cancer	1.66e-06	2.41e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—prostate cancer	1.65e-06	2.39e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FGF2—prostate cancer	1.65e-06	2.39e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CB—prostate cancer	1.64e-06	2.38e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PPARA—prostate cancer	1.63e-06	2.36e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APC—prostate cancer	1.63e-06	2.36e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CG—prostate cancer	1.63e-06	2.36e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—P4HB—prostate cancer	1.63e-06	2.36e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOS3—prostate cancer	1.62e-06	2.35e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TYMS—prostate cancer	1.61e-06	2.34e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGF—prostate cancer	1.61e-06	2.33e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IRS1—prostate cancer	1.61e-06	2.33e-05	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—AKT1—prostate cancer	1.61e-06	2.33e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTM1—prostate cancer	1.59e-06	2.31e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.58e-06	2.3e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—JAK2—prostate cancer	1.58e-06	2.29e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCL8—prostate cancer	1.58e-06	2.29e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—LPL—prostate cancer	1.56e-06	2.27e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GSK3B—prostate cancer	1.56e-06	2.27e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CA—prostate cancer	1.55e-06	2.24e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.54e-06	2.24e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—INS—prostate cancer	1.54e-06	2.23e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1B—prostate cancer	1.54e-06	2.23e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MDM2—prostate cancer	1.54e-06	2.23e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CAV1—prostate cancer	1.53e-06	2.22e-05	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AKT1—prostate cancer	1.52e-06	2.21e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—MED12—prostate cancer	1.52e-06	2.2e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ERBB2—prostate cancer	1.52e-06	2.2e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP1A1—prostate cancer	1.51e-06	2.19e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CREBBP—prostate cancer	1.51e-06	2.19e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CASP3—prostate cancer	1.51e-06	2.19e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL2—prostate cancer	1.51e-06	2.18e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GNG5—prostate cancer	1.51e-06	2.18e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL6—prostate cancer	1.5e-06	2.17e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CB—prostate cancer	1.5e-06	2.17e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ERCC2—prostate cancer	1.5e-06	2.17e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IGF1—prostate cancer	1.49e-06	2.16e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCND1—prostate cancer	1.47e-06	2.13e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CTNNB1—prostate cancer	1.46e-06	2.11e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NCOA3—prostate cancer	1.45e-06	2.1e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAP2K1—prostate cancer	1.44e-06	2.09e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTEN—prostate cancer	1.44e-06	2.09e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCL8—prostate cancer	1.44e-06	2.09e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CD—prostate cancer	1.43e-06	2.08e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MMP9—prostate cancer	1.43e-06	2.07e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1A—prostate cancer	1.42e-06	2.06e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTEN—prostate cancer	1.42e-06	2.06e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SERPINE1—prostate cancer	1.42e-06	2.05e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—MTHFR—prostate cancer	1.41e-06	2.04e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1B—prostate cancer	1.41e-06	2.04e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CG—prostate cancer	1.4e-06	2.03e-05	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AKT1—prostate cancer	1.39e-06	2.02e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HPGDS—prostate cancer	1.38e-06	2.01e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AKT1—prostate cancer	1.38e-06	2.01e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PPARA—prostate cancer	1.38e-06	2e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MYC—prostate cancer	1.38e-06	2e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CASP3—prostate cancer	1.38e-06	2e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL2—prostate cancer	1.38e-06	1.99e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.38e-06	1.99e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—EP300—prostate cancer	1.37e-06	1.99e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FGF2—prostate cancer	1.37e-06	1.99e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL6—prostate cancer	1.37e-06	1.98e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EP300—prostate cancer	1.35e-06	1.96e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOS3—prostate cancer	1.35e-06	1.96e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTT1—prostate cancer	1.34e-06	1.95e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ACHE—prostate cancer	1.34e-06	1.95e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCND1—prostate cancer	1.34e-06	1.94e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CTNNB1—prostate cancer	1.33e-06	1.93e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.33e-06	1.92e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—INS—prostate cancer	1.32e-06	1.92e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SRC—prostate cancer	1.32e-06	1.91e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—JAK2—prostate cancer	1.31e-06	1.9e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MMP9—prostate cancer	1.3e-06	1.89e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CAV1—prostate cancer	1.3e-06	1.88e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1A—prostate cancer	1.3e-06	1.88e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CREBBP—prostate cancer	1.3e-06	1.88e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTEN—prostate cancer	1.3e-06	1.88e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.29e-06	1.87e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PRKACB—prostate cancer	1.28e-06	1.86e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MDM2—prostate cancer	1.28e-06	1.86e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—prostate cancer	1.28e-06	1.86e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.27e-06	1.84e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STAT3—prostate cancer	1.27e-06	1.84e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ERBB2—prostate cancer	1.27e-06	1.83e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AKT1—prostate cancer	1.26e-06	1.83e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CB—prostate cancer	1.25e-06	1.81e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.24e-06	1.8e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EP300—prostate cancer	1.24e-06	1.79e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CD—prostate cancer	1.23e-06	1.78e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NCOA2—prostate cancer	1.21e-06	1.76e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SRC—prostate cancer	1.2e-06	1.74e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCL8—prostate cancer	1.2e-06	1.74e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.18e-06	1.71e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MYC—prostate cancer	1.18e-06	1.71e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TGFB1—prostate cancer	1.18e-06	1.7e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1B—prostate cancer	1.17e-06	1.7e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—prostate cancer	1.17e-06	1.69e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NOS3—prostate cancer	1.16e-06	1.68e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STAT3—prostate cancer	1.16e-06	1.68e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.16e-06	1.67e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGFR—prostate cancer	1.15e-06	1.67e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CASP3—prostate cancer	1.15e-06	1.66e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL2—prostate cancer	1.15e-06	1.66e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.13e-06	1.64e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—INS—prostate cancer	1.12e-06	1.62e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCND1—prostate cancer	1.12e-06	1.62e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NQO1—prostate cancer	1.12e-06	1.62e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CTNNB1—prostate cancer	1.11e-06	1.6e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TH—prostate cancer	1.1e-06	1.59e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CREBBP—prostate cancer	1.1e-06	1.59e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KRAS—prostate cancer	1.09e-06	1.58e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MMP9—prostate cancer	1.09e-06	1.57e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1A—prostate cancer	1.08e-06	1.57e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTEN—prostate cancer	1.08e-06	1.56e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MYC—prostate cancer	1.08e-06	1.56e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TGFB1—prostate cancer	1.07e-06	1.56e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CB—prostate cancer	1.07e-06	1.55e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.07e-06	1.55e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—prostate cancer	1.06e-06	1.54e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGFR—prostate cancer	1.05e-06	1.53e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.04e-06	1.51e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GGT1—prostate cancer	1.04e-06	1.5e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EP300—prostate cancer	1.03e-06	1.49e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NCOA1—prostate cancer	1.02e-06	1.48e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CA—prostate cancer	1.02e-06	1.47e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.01e-06	1.46e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CA—prostate cancer	1e-06	1.45e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SRC—prostate cancer	1e-06	1.45e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KRAS—prostate cancer	9.95e-07	1.44e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NOS3—prostate cancer	9.82e-07	1.42e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—prostate cancer	9.75e-07	1.41e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—RXRA—prostate cancer	9.71e-07	1.41e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—prostate cancer	9.68e-07	1.4e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STAT3—prostate cancer	9.65e-07	1.4e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—AKT1—prostate cancer	9.56e-07	1.39e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—COMT—prostate cancer	9.35e-07	1.36e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTP1—prostate cancer	9.31e-07	1.35e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTEN—prostate cancer	9.26e-07	1.34e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ITPR1—prostate cancer	9.16e-07	1.33e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	9.14e-07	1.32e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CB—prostate cancer	9.07e-07	1.31e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—prostate cancer	8.99e-07	1.3e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MYC—prostate cancer	8.97e-07	1.3e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TGFB1—prostate cancer	8.94e-07	1.3e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL6—prostate cancer	8.86e-07	1.28e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—prostate cancer	8.84e-07	1.28e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—EP300—prostate cancer	8.83e-07	1.28e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGFR—prostate cancer	8.77e-07	1.27e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TYMS—prostate cancer	8.65e-07	1.25e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTM1—prostate cancer	8.55e-07	1.24e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—LPL—prostate cancer	8.4e-07	1.22e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AKT1—prostate cancer	8.31e-07	1.2e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KRAS—prostate cancer	8.28e-07	1.2e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKT1—prostate cancer	8.18e-07	1.18e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP1A1—prostate cancer	8.11e-07	1.17e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL6—prostate cancer	8.09e-07	1.17e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ERCC2—prostate cancer	8.04e-07	1.17e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTEN—prostate cancer	7.84e-07	1.14e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CA—prostate cancer	7.61e-07	1.1e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—MTHFR—prostate cancer	7.56e-07	1.1e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—EP300—prostate cancer	7.47e-07	1.08e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKT1—prostate cancer	7.46e-07	1.08e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPARA—prostate cancer	7.42e-07	1.07e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—prostate cancer	7.36e-07	1.07e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CAV1—prostate cancer	6.97e-07	1.01e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL6—prostate cancer	6.74e-07	9.76e-06	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CA—prostate cancer	6.53e-07	9.46e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CG—prostate cancer	6.35e-07	9.2e-06	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKT1—prostate cancer	6.22e-07	9.01e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—INS—prostate cancer	6.01e-07	8.71e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CREBBP—prostate cancer	5.89e-07	8.53e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CD—prostate cancer	5.58e-07	8.09e-06	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CA—prostate cancer	5.53e-07	8.01e-06	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKT1—prostate cancer	5.33e-07	7.73e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NOS3—prostate cancer	5.27e-07	7.64e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CB—prostate cancer	4.87e-07	7.05e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—prostate cancer	4.82e-07	6.99e-06	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKT1—prostate cancer	4.52e-07	6.54e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTEN—prostate cancer	4.21e-07	6.09e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—EP300—prostate cancer	4.01e-07	5.81e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.97e-07	4.3e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKT1—prostate cancer	2.42e-07	3.51e-06	CbGpPWpGaD
